ESPE2015

1 October 2015

07:30-19:00Registration
08:00-11:00Working Group WG1 - ESPE Bone and Growth Plate (BGP) Working Group
Chair(s): Ola Nilsson (Stockholm, Sweden) & Gabriele Häusler (Vienna, Austria)
Hall 3
08:00WG1.1Short stature: blame the chondrocyte
08:30WG1.2The role of NFkB in growth plate chondrogenesis
09:00Coffee Break
09:30WG1.3Genetics of juvenile osteoporosis
10:00WG1.4Bone tissue characteristics in pediatric bone disease
10:30WG1.5Fracture prevention in cystic fibrosis
08:00-11:00Working Group WG2 - ESPE Working Group on Diabetes Technology and Therapeutics
Chair(s): Moshe Phillip (Petah Tikva, Israel) & Tadej Battelino (Ljubljana, Slovenia)
Hall 1
08:00Introductions
08:05WG2.1New technologies in treating patients with type 2 diabetes
08:30WG2.2Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes?
08:30WG2.3Debate: Are genetic tests necessary before starting a treatment of a patient with Neonatal Diabetes?
09:10Coffee Break
09:30WG2.4Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand?
09:31WG2.5Debate: Blood glucose monitoring - which is the better: continuous real-time or episodic real-time on demand?
10:10WG2.6Type 2 diabetes mellitus in adolescence
10:35WG2.7The rationale and potential role of surgery in the treatment of adolescent diabetes
08:00-11:00Working Group WG3 - ESPE Working Group on Disorders of Sex Development (DSD)
Chair(s): Paul Martin Holterhus (Kiel, Germany) & Anna Nordenström (Stockholm, Sweden)
Hall 2
08:00Welcome
08:00WG3.1Maternal, placental and fetal steroid hormone synthesis: the key facts for understanding DSDs
08:30WG3.2DSD in Indonesia: the course of psychological development in late identified patients
09:00Coffee Break
09:30WG3.3Work accomplished by the European Reference Network
10:15WG3.4I-DSD and I-CAH registry update
10:30WG3.5EU-Study: dsd-LIFE
10:45DSD Open Business Meeting
08:00-11:00Working Group WG4 - ESPE Obesity Working Group (OWG)
Chair(s): Jesús Argente (Madrid, Spain) & Bessie Spiliotis (Patras, Greece)
Hall 7
08:00WG4.1The endocrine role of brown adipose tissue
08:40WG4.2A monomeric peptide triagonist for the treatment of obesity and diabetes
09:20Coffee Break
09:40WG4.3Genetic approach to understanding severe early-onset childhood obesity
10:20WG4.4Understanding gene-diet interactions as an approach for the treatment of obesity
08:00-11:00Working Group WG5 - ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
Chair(s): Marco Cappa (Rome, Italy) & Charles Sultan (Montpellier, France)
Hall 4
08:00WG5.1Impact of malignancies and their treatment on reproductive function in girls
08:30WG5.2Preservation of fertility pre-therapy
09:00WG5.3Restoration of fertility in cancer adolescents after chemotherapy
09:30Coffee Break
10:00WG5.4Diagnosis and management of endometriosis in adolescence
10:30WG5.5Uterus transplantation with live births – an update
08:00-11:00Working Group WG6 - ESPE Working Group on Turner Syndrome (TS)
Chair(s): Siska Verlinde & Malcolm Donaldson / Ewa Malecka-Tendera & Jenielle van Alfen
Hall 5
08:00Welcome
08:05WG6.1Incidental prenatal diagnosis of Turner Syndrome, perspectives of parents and professionals
08:45WG6.2The challenges of prenatal diagnosis: the experience of a supportive group for parents of children with TS
09:15Coffee Break
09:30WG6.3Impact of age at start and GH dose for height gain and age at adult height in TS girls
10:00WG6.4Management of middle ear and hearing problems in Turner's syndrome - how can we do better?
10:30WG6.5Report on the progress and difficulties on transdermal Estradiol supplementation in Europe
11:15-11:30Opening Ceremony
Hall 1
11:30-12:00Plenary 1
Chair(s): Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain)
Joint ESPE-ISPAD Session
Hall 1
11:30PL1Genetic and environmental determinants of type 1 diabetes
12:00-12:30Plenary 2
Chair(s): Ragnar Hanas (Uddevalla, Sweden) & Luis Castaño (Bilbao, Spain)
Joint ESPE-ISPAD Session
Hall 1
12:00PL2New advances in monogenetic diabetes
12:30-14:00Lunch, Visit to Posters and Exhibition
12:30-13:30P1 Mini-Poster Presentations
Adrenal: P1-1 to P1-11
Bone: P1-12 to P1-22
Diabetes: P1-23 to P1-33
Growth Hormone: P1-78 to P1-88
Perinatal: P1-100 to P1-110
12:45-13:45Industry Sponsored Satellite Symposium 1
14:00-15:30Symposium 1 - The effect of hormonal abnormalities on Neurocognition
Chair(s): Jesús Argente (Madrid, Spain) & George Chrousos (Athens, Greece)
Hall 3
14:00S1.1The effect of thyroid hormones on the brain
14:30S1.2The effect of diabetes mellitus on neurocognition
15:00S1.3The effects of growth hormone and anabolic androgenic steroids on the brain
14:00-15:30Symposium 2 - Adipose tissue: Beyond classical concepts
Chair(s): Martin Wabistch (Ulm, Germany) & Antje Körner (Leipzig, Germany)
Hall 5
14:00S2.1Brown adipose tissue and its therapeutic potential
14:30S2.2Is brown adipose tissue relevant to paediatrics?
15:00S2.3Lipodystrophies: new approaches for diagnostic workup and treatment
14:00-15:30Symposium 3 - Disorders of sex development: An update
Chair(s): Nils Krone (Sheffield, UK) & Olaf Hiort (Luebeck, Germany)
Hall 2
14:00S3.1Novel genes identified in male and female sex development
14:30S3.2Decision Making in DSD: Development of a Decision Support Tool.
15:00S3.3Genetic and enviromental disruption of testicular function
14:00-15:30Symposium 4 - Management of thyroid disorders: Current best practice
Chair(s): Jan-Maarten Wit (Leiden, The Netherlands) & Annette Greuters-Kieslich (Berlin, Germany)
Hall 1
14:00S4.1Screening, diagnosis and management of congenital hypothyroidism
14:30S4.2Management of hyperthyroidism in children
15:00S4.3Genetics of congenital hypothyroidism and associated problems
15:30-16:00Coffee Break
16:00-17:00Meet the Expert Sessions
MTE1.1Management of adrenal tumours
MTE2.1Translation of diabetes technologies to clinical practice
MTE3.1Challenges in the management of short stature
MTE4.1Use of hormone replacement in females with endocrine disorders
16:00-17:00Controversies 1: Debate - Is bariatric surgery the management of choice for obese adolescents?
Chair(s): Wieland Kiess (Leipzig, Germany) & Bessie Spiliotis (Athens, Greece)
Hall 4
For the Motion
Against the Motion
16:00-17:00Yearbook of Paediatric Endocrinology
Chair(s): Franco Chiarelli (Chieti, Italy)
Hall 1
YB1.1Obesity and weight regulation
YB1.2Type 2 diabetes, metabolic syndrome and lipids
YB1.3Type 1 diabetes
YB1.4Evidence based medicine in pediatric endocrinology
YB1.5Editor's choice
17:15-18:45Industry Sponsored Satellite Symposium 2 - 4
18:45-Welcome Reception
Exhibition area

2 October 2015

07:30-19:00Registration
08:00-09:00Meet the Expert Sessions
MTE8.1Looking beyond nutritional rickets: From the foetus to the infant
MTE5.1Management of the adolescent with CAH
MTE6.1Management of Prader-Willi syndrome in toddlers
MTE7.1Management of late-effects in the child/adolescent with cancer
09:15-10:15Free Communications 1 - Adrenal
Chair(s): Berenice Mendonca (Sao Paulo, Brazil) & Christa Flück (Bern, Switzerland)
Hall 2
09:15FC1.1A genomic atlas of human gonad and adrenal development
09:25FC1.2Involvement of the Wnt/beta-catenin pathway, SF1, DAX1 and stem/progenitor cell markers in paediatric adrenocortical tumors (ACTs)
09:35FC1.3 Aldosterone and mineralocorticoid receptor as inducers of immune markers in peripheral blood mononuclear cells: beyond elevating blood pressure
09:45FC1.4Congenital adrenal hyperplasia due to 21 OH deficiency: final height before and after newborn screening era in Emilia-Romagna region, Italy
09:55FC1.5Atypical presentation of six patients with mutations in the side chain cleavage enzyme CYP11A1
10:05FC1.6An update on noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free foetal DNA in maternal plasma
09:15-10:15Free Communications 2 - Bone & Mineral Metabolism
Chair(s): Dov Tosiano (Israel) & Serap Turan (Istanbul, Turkey)
Hall 3
09:15FC2.1Whole exome sequencing analysis of patients with autosomal recessive hypophophatemic rickets identified mutations in DMP1, ENPP1 and SLC34A3
09:25FC2.2Identification of mutations in TBX1 and AIRE in isolated hypoparathyroidism patients
09:35FC2.3High success of a next generation sequencing panel for the molecular diagnosis of rare skeletal dysplasias
09:45FC2.4Asfotase alfa: sustained efficacy and tolerability in children with hypophosphatasia treated for 5 years
09:55FC2.5Methyl donor deficiency impairs differentiation of pre-osteoblasts through disruption of functional interaction between peroxisome proliferator-activated receptor-gamma coactivator-1 alpha and vitamin D receptor
10:05FC2.6A contextual feature-based recognition approach to quantify trabecular microstructure using 1.5T axial-MRI: an innovative methodology
09:15-10:15Free Communications 3 - Diabetes
Chair(s): Alfonso Lechuga (Spain) & Silva Arslanian
Hall 4
09:15FC3.1RNA-based MAFA over-expression is sufficient to drive human pancreatic duct-derived cells toward a -cell-like phenotype
09:25FC3.2Experience with molecular diagnosis in 48 cases of neonatal diabetes mellitus using targeted next-generation sequencing
09:35FC3.3Clinical characteristics and molecular genetic analysis of 6 patients with pancreas aplasia and neonatal diabetes: predominance of PTF1A-enhancer mutations
09:45FC3.4Wolfram syndrome: natural history and genotype-phenotype correlation based on EURO-WABB Registry show gender differences in disease severity
09:55FC3.5C-peptide levels and glycemic control in children, adolescents and young adults with type 1 diabetes (TID)
10:05FC3.6First report of nationwide incidence and prevalence of type 1 diabetes among children in Turkey
09:15-10:15Free Communications 4 - Growth
Chair(s): Jovanna Dahlgren & Gary Butler (London, UK)
Hall 5
09:15FC4.1Heterozygous dominant negative STAT5B variants associated with short stature and GH insensitivity
09:25FC4.2A recurrent homozygous NDUFB3 mutation, p.Trp22Arg causes a short stature disorder and mitochondrial protein complex I deficiency with a variable metabolic phenotype
09:35FC4.3An updated and final analysis of a randomised placebo-controlled trial of the effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome
09:45FC4.4Modulation of GH-1 splicing as potential strategy to rescue growth hormone deficiency type II
09:55FC4.5Stunted growth after inhaled corticosteroid use during the first 24 months of life
10:05FC4.6Positive association between height and cancer in the Swedish population
09:15-10:15Free Communications 5 - Endocrine Oncology / Turner Syndrome
Chair(s): (Mohammed Maghnie (Genoa, Italy) & Cristina Azcona (Pamplona, Spain)
Hall 7
09:15FC5.1Resveratrol potentiates growth inhibitory effects of rapamycin in PTEN-deficient lipoma cells by suppressing p70S6 kinase activity
09:25FC5.2MEN1 syndrome because of combined germline and somatic mosaicism, with important consequences for relatives
09:35FC5.3Screening in children with Succinate dehydrogenase B (SDHB) mutations: a single centre’s family clinic experience
09:45FC5.4X chromosome gene dosage and the risk of developing congenital and acquired traits in Turner syndrome: a cross-sectional database analysis of the French national rare disease network
09:55FC5.5Hereditary Turner syndrome 46,X,rec(X)inv(p21q28) in six women and four generations: estimation of skeletal effects of growth hormone treatment
10:05FC5.6Anti-Müllerian hormone levels in patients with Turner syndrome: relation to karyotype, pubertal development and growth hormone therapy
09:15-10:15Yearbook of Paediatric Endocrinology
Chair(s): Primus Mullis (Bern, Switzerland)
Hall 1
YB2.1Pituitary and neuroendocrinology
YB2.2Reproductive Endocrinology
YB2.3Antenatal and Neonatal Endocrinology
YB2.4Growth and growth factors
YB2.5Type 1 diabetes
09:15-10:15New Perspectives Session 1
Chair(s): Cheri Deal (Montreal, Canada)
Hall 6
NP1.1Pancreatic development using zebrafish as a model
NP1.2Optogenetic control of neuroendocrine hormone secretion
10:45-11:15Plenary 3
Chair(s): Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK)
Hall 1
10:45PL3New advances in human evolution from the analysis of ancient genomes
11:15-12:15ESPE Awards and Activities 1
Chair(s): Anita Hokken-Koelega (Rotterdam, The Netherlands) & Jan Lebl (Prague, Czech Republic)
Hall 1
ESPE Young Investigator Award 1 & 2 – sponsored by Pfizer
ESPE Schools – sponsored by ESPE (Diabetes, Obesity and Metabolism School), Ferring Pharmaceuticals (Summer, Winter and Caucasus & Central Asia Schools), Novo Nordisk Gulf (ASPED-ESPE School), and Pfizer (Maghreb School)
ESPE Fellowships and Sabbatical Leave Programme – sponsored by Novo Nordisk A/S (Research Fellowship), Merck Serono SA (Clinical Fellowship) and Eli Lilly and Company (Sabbatical Leave Programme)
ESPE Hormone Research in Paediatrics Prizes – sponsored by Karger A.G.
ESPE International Award – sponsored by Pfizer
ESPE Research Award – sponsored by Pfizer
12:15-12:45Plenary 4
Chair(s): Jean-Claude Carel (Paris, France) & Mehul Dattani (London, UK)
Hall 1
12:15PL4Genomic diversity in present day humans: Evolutionary aspects
12:45-14:30Lunch, Visit to the Posters and Exhibition
12:45-13:45P1 Mini Poster Presentations
Diabetes: P1-34 to P1-44
DSD: P1-56 to P1-66
Growth: P1-89 to P1-99
Turner & Puberty: P1-133 to P1-143
Misc: P1-144 to P1-154
13:15-14:15Industry Sponsored Satellite Symposium 5
14:15-16:15ESPE Working Group for Paediatic Endocrine Nurse Specialists and Allied Health Professionals (PENSWG)
Chair(s): Kate Davies (London, UK) & Christine Derycke (Brussels, Belgium)
Hall 6
14:15WG7.1Nurse run short stature screening clinic
14:35WG7.2Quality management initiatives in pediatric endocrinology: Selected case study and clinical initiatives
14:55Q & A from the first two speakers
15:10WG7.3Getting a patient off of medication due to coaching and care. A case report
15:20WG7.4Long-term outcome of a male preschooler treated for central precocious puberty
15:30WG7.5Pan-Canadian experience of pediatric endocrine nurses assisting youth through gender transition
15:40Q & A from the above case study speakers
15:55WG7.6Sharing Resources:  Hypothyroidism 
14:30-16:00Symposium 5 - Developmental Programming: Novel concepts
Chair(s): Stefano Cianfarani (Rome, Italy) & Ruben Diaz (Spain)
Hall 5
14:30S5.1Developmental programming of reproductive function: Early life nutritional impacts
15:00S5.2Transgenerational developmental programming of endocrine disease
15:30S5.3Intergenerational programming of metabolic disease
14:30-16:00Symposium 6 - Type 2 Diabetes & Obesity
Chair(s): Tadej Battelino (Ljubljana, Slovenia) & Jan Lebl (Prague, Czech Republic)
Hall 1
14:30S6.1Can genotype be used to tailor treatment of obesity?
15:00S6.2New and old drugs for treatment of type 2 diabetes in children
15:30S6.3From obesity to type 2 diabetes
14:30-16:00Symposium 7 - Hypogonadotropic hypogonadism: diagnostic and therapeutic approach
Chair(s): Nicholas de Roux (Paris, France) & Maria Clemente
Hall 2
14:30S7.1Early therapeutic approach to the male patient with HH
15:00S7.2Pubertal induction and fertility prospects in the male
15:30S7.3Modeling GnRH deficiency with the use of human pluripotent cells
14:30-15:30Controversies 2: Debate - Should pre-natal treatment for CAH be offered?
Chair(s): Peter Hindmarsh (London, UK)
Hall 4
For the Motion
Against the Motion
14:30-16:00Special Symposium - Recommendations for surveillance for thyroid cancer in survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Chair(s): Hanneke van Santen
Hall 3
14:30SS1.1Introduction of the IGHG-thyroid group, its members and aims
14:35SS1.2Methodology of the IGHG recommendations
14:45SS1.3Which cancer survivors are at risk for thyroid cancer; summary of the evidence
15:00SS1.4Is detection of thyroid cancer in an early stage beneficial ?
15:10SS1.5Which evaluation modality is most sensitive and specific for detecting thyroid carcinoma in an early stage; summary of the evidence and decision tree analysis.
15:20SS1.6Pro-Con debate - Arguments in favour of screening survivors at risk with palpation of the neck
15:35SS1.6Pro - Con Debate: Arguments in favour of screening survivors at risk with thyroid ultrasound
15:50SS1.7Further steps of the IGHG group; forming a decision aid.
14:30-16:00Special Symposium - Opportunities and challenges in accessing essential medications in low and middle income countries
Chair(s): Reiko Horikawa (Japan)
Hall 7
14:30SS2.1Facilitating Access to Essential Medicines: role of WHO
15:00SS2.2Bringing essential medicines into low income countries: opportunities and challenges for the pharmaceutical
15:30SS2.3A model for the sustainable access to medicines for the management of congenital adrenal hyperplasia (CAH) in a low income setting
16:15-17:45ESPE Annual Business Meeting
ESPE Members Only
18:00-19:30Industry Sponsored Satellite Symposium 6 - 8

3 October 2015

07:30-18:30Registration
08:00-09:00Meet the Expert Sessions
MTE1.2Management of adrenal tumours
MTE3.2Challenges in the management of short stature
MTE4.2Use of hormone replacement in females with endocrine disorders
MTE7.2Management of late-effects in the child/adolescent with cancer
MTE2.2Translation of diabetes technologies to clinical practice
09:15-10:15New Perspectives Session 2
Chair(s): Ze'ev Hochberg (Haifa, Israel) & Gabriele Haeusler
Hall 7
NP2.1Engineering cartilage
NP2.2Astrocytes and neuroendocrine control
09:15-10:15New Technologies Session
Chair(s): Ken Ong (Cambridge, UK) & Laura De Graff (The Netherlands)
Hall 6
NT1New technologies in imaging
NT2Next Generation Sequencing: Implementing the 100,000 genome project for treatment of NHS patients
09:15-10:15Free Communications 6 - Gonads & DSD
Chair(s): Tsutomu Ogata (Japan) & John Achermann (London, UK)
Hall 1
09:15FC6.1Correlation of AR expression and AR transcriptional activity in cultured human genital fibroblasts
09:25FC6.2A role for DMRT1 in human primary sex-determination
09:35FC6.3Establishing the role of the steroid backdoor pathway for androgen biosynthesis in the human ovary
09:45FC6.4Severe 46, XY disorder of sex development (DSD) due to CBX2 isoform 2 mutation is distinct from CBX2.1 deficiency and is likely due to EMX2 dysregulation in the human developing gonad
09:55FC6.5Characterisation of mutations in the androgen receptor (AR) identified in 38 Brazilian families with complete or partial androgen insensitivity syndrome (AIS)
10:05FC6.6Frequency of gonadal tumour in complete androgen insensitivity syndrome (CAIS): a retrospective case-series analysis
09:15-10:15Free Communications 7 - Growth promoting therapies
Chair(s): Gerhard Binder (Tuebingen, Germany) & Alexander Augusto de Lima Jorge (São Paulo, Brazil)
Hall 2
09:15FC7.1Safety and effectiveness of Increlex® therapy in children with Laron syndrome and enrolled in the European Increlex® Growth Forum Database (EU-IGFD) in Europe
09:25FC7.2Topicon™ ThermoMatrix™-mediated passive transdermal delivery of insulin-like growth factor 1 (IGF-1) Across EpidermFT™ full-thickness human skin equivalent (HSE): towards an extended-wear IGF-1 Patch
09:35FC7.3IGF-I levels, complex formation and igf-bioactivity in growth hormone treated children with Prader-Willi syndrome
09:45FC7.4A novel reversible albumin-binding growth hormone derivative possesses a promising once-weekly treatment profile in children with growth hormone deficiency
09:55FC7.512 month safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary
10:05FC7.6Pharmacokinetic (PK) and pharmacodynamics (PD) modelling of MOD 4023 (a long-acting human growth hormone (hGH)) in growth hormone deficient (GHD) children
09:15-10:15Free Communications 8 - Obesity Basic
Chair(s): Jean-Pierre Chanoine & Carlo Acerini (Cambridge, UK)
Hall 3
09:15FC8.1DLK1 expression in adipose tissue following fetal growth restriction: relation to visceral fat expansion and catch-up growth in Wistar rats
09:25FC8.2Apoptosis inhibitor of macrophages (AIM): an anti-inflammatory adipocyte factor in mild adolescent obesity?
09:35FC8.3Testing the Appetite Suppressing Effects of Vitamin B12 Conjugates of Peptide YY
09:45FC8.4Severe early-onset obesity caused by bioinactive leptin due to a N103K mutation
09:55FC8.5Adipocytokines in placenta and cord blood in relation to maternal obesity, and foetal and postnatal growth of the child
10:05FC8.6Metabolic effects of ADP355, protein-based adiponectin receptor agonist, on mice with high-fat diet induced fatty liver disease
09:15-10:15Free Communications 9 - Beta cell disorders
Chair(s): John Gregory (Cardiff, UK) & Ritika Kapoor
Hall 4
09:15FC9.1Islet δ-cells contribute to the pathobiology of atypical congenital hyperinsulinism
09:25FC9.2A novel source of mesenchymal stem cells lines from the human neonatal pancreas of patients with congenital hyperinsulinism in infancy
09:35FC9.3Failure to terminate cell proliferation contributes to the pathobiology of congenital hyperinsulinism in infancy
09:45FC9.4Novel molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8
09:55FC9.5The use of glucagon for management of severe-persistent hypoglycaemia in patients with congenital hyperinsulinism
10:05FC9.6Pharmacokinetics (PK) of a new suspension of glibenclamide for use in young patients and infants with neonatal diabetes
10:45-11:45ESPE Awards and Activities 2
Chair(s): Laura Audí (Barcelona, Spain) & Lars Sävendahl (Stockholm, Sweden)
Hall 1
Henning Andersen Prizes – sponsored by Novo Nordisk A/S
ESPE Research Unit – sponsored by ESPE and Sandoz International GmbH
IFCAH-ESPE award – supported by The International Fund for Research on Congenital Adrenal Hyperplasia
ESPE Outstanding Clinician Award – sponsored by Pfizer
ESPE International Outstanding Clinician Award – sponsored by Pfizer
Andrea Prader Prize – sponsored by Pfizer
11:45-12:15Plenary 5
Chair(s): Lourdes Ibanez
Hall 1
11:45PL5Ontogeny of FGF21 in the human: Implications for metabolic health
12:30-13:30Yearbook of Paediatric Endocrinology
Chair(s): Juliane Léger (Paris, France)
Hall 1
YB3.1Adrenals
YB3.2THyroid
YB3.3Bone, Growth plate and mineral metabolism
YB3.4Oncology and chronic disease
YB3.5The Year in Science and Medicine
12:30-13:30Free Communications 10 - Perinatal endocrinology
Chair(s): Rod Mitchell (Edinburgh, UK) & Irène Netchine (Paris, France)
Hall 2
12:30FC10.1Effect of sonic hedgehog signalling on regulation the expression of 11β-HSD2 in the placenta
12:40FC10.2The altered circulating miRNA profile in maternal obesity associate with pre- and post-natal growth
12:50FC10.3Circulating miRNA expression profile in pregestational and gestational obesity
13:00FC10.4Effect of P450 oxidoreductase variants on metabolism by cytochrome P450 proteins
13:10FC10.5Lack of association between transient hypothyroxinaemia of prematurity and neurodevelopmental and behavioral outcomes in young adulthood
13:20FC10.6Heterozygous hypomorphic mutation in the INS gene could cause transient neonatal diabetes in extremely low birth weight neonates
12:30-13:30Free Communications 11 - Neuroendocrinology
Chair(s): Ivo Arnhold (Sao Paulo, Brazil) & Malcolm Donaldson (Glasgow, Scotland)
Hall 3
12:30FC11.1Mutations in BRAF are associated with septo-optic dysplasia and cardiofaciocutaneous syndrome
12:40FC11.2Functional characterisation of a POU1F1 mutation unexpectedly associated with isolated growth hormone deficiency (IGHD): a novel aetiology of IGHD
12:50FC11.3Next generation sequencing: towards a new clinical frontier in the diagnosis and management of pituitary tumours
13:00FC11.4Idiopathic multiple pituitary hormone deficiency (IMPHD): radiological and perinatal factors
13:10FC11.5Endocrinopathy after intracranial germ cell tumours (IGCT) is disease not radiation- related: two decades of surveillance in a large tertiary paediatric cohort
13:20FC11.6Long-term outcome of patients treated for paediatric Cushing's disease
12:30-13:30Free Communications 12 - Obesity clinical
Chair(s): Juan-Pedro Lopez-Siguero & Veronica Mericq
Hall 4
12:30FC12.1Evaluation of cardiovascular risk in childhood: data from a survey of dyslipidaemic children
12:40FC12.2Soluble CD163, a circulating marker of macrophage activation, associates with a less favourable metabolic profile in children
12:50FC12.3Re-classification of childhood obesity by steroid metabolomic disease signature
13:00FC12.4RM-493, a melanocortin-4 receptor (MC4R) agonist, is being therapeutically evaluated in patients with deficiencies in the Leptin – Proopiomelanocortin (POMC) – MC4R hypothalamic pathway, including Prader-Willi syndrome (PWS)
13:10FC12.5Link between body mass index and insulin requirement in children and young people with type 1 diabetes mellitus
13:20FC12.6Initial experience with endoscopically placed duodenal-jejunal bypass liner (Endobarrier®) in morbidly obese adolescents
12:30-13:30Free Communications 13 - Thyroid
Chair(s): Michel Polak (Paris, France)
Hall 5
12:30FC13.1Gain of function STAT3 mutation in a boy with early onset autoimmune diabetes and thyroid disease, prenatal and postnatal growth impairment and lymphoproliferation
12:40FC13.2Analysis of chosen polymorphisms rs2476601 A/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 A/G - TSHR in pathogenesis of autoimmune thyroid diseases in children
12:50FC13.3Targeted next-generation sequencing demonstrates high frequency of ‘dyshormonogenesis genes’ mutations in severe congenital hypothyroidism
13:00FC13.4Effects of initial levothyroxine dose on growth and neurodevelopmental outcomes during the first year of life in children with congenital hypothyroidism
13:10FC13.5Effect of two years of treatment with levothyroxine on cardiovascular risk factors in children with mild idiopathic subclinical hypothyroidism
13:20FC13.6TRIAC treatment of allan-herndon-dudley syndrome (AHDS) due to defects in thyroid hormone transporter MCT8
12:30-13:30Free Communications 14 - Puberty
Chair(s): Dolores Rodriquez-Amao & Abdullah Bereket
Hall 7
12:30FC14.1KLB, encoding the co-receptor for FGF21, is mutated in congenital hypogonadotropic hypogonadism
12:40FC14.2A mutation in HS6ST1 causes self-limited delayed puberty
12:50FC14.3The new syndrome of hypogonadotropic hypogonadism, arrythmogenic right ventricular dysplasia, facial dysmorphism and absence of corpus callosum is associated to TAX1 binding protein 3 gene mutation
13:00FC14.4Genetic variation of AMH signaling affects AMH and inhibin B levels in healthy peripubertal girls
13:10FC14.5Polybrominated diphenyl ethers (PBDEs) and timing of puberty in girls
13:20FC14.6An evaluation of glandular breast tissue development and volume by MRI in 121 healthy peripubertal girls
12:30-13:30Free Communications 15 - Late Breaking
Chair(s): Carlos Longui & Olle Söder (Stockholm, Sweden)
Hall 6
12:30FC-LB-1RNA Sequencing Reveals The Pathways Perturbed by Redox Imbalance in Nicotinamide Nucleotide Transhydrogenase null mice.
12:40FC-LB-2Loss of Neuronal Dmxl2 impairs the maturation and the activation of GnRH neurons: a new mechanism of GnRH deficiency.
12:50FC-LB-3Pharmacokinetic and Pharmacodynamic Studies of Topicon™-Mediated Patch Delivery of Insulin Glargine in a Streptozotocin-Induced Hairless Rat Model
13:00FC-LB-4Long-term cognitive effects of antenatal dexamethasone treatment in Swedish adolescents with and without CAH
13:10FC-LB-5Paternally inherited IGF2 mutation results in intrauterine and postnatal growth retardation
13:20FC-LB-6PROP1 mutations cause hypopituitarism by disrupting the transition of pituitary stem cells to differentiation
13:30-Lunch, Visit to the Posters and Exhibition
13:30-14:30P1 Mini Poster Presentations
Diabetes: P1-45 to P1-55
Fat: P1-67 to P1-77
Puberty: P1-111 to P1-121
Thyroid: P1-122 to P1-132
Misc: P1-155 to P1-165
13:45-15:15ESPE Education and Training
Hall 6
14:00-15:00Industry Sponsored Satellite Symposium 9
15:30-17:00Symposium 8 - Diabetes & Obesity as infectious diseases
Chair(s): Maria Chueca (Spain) & Zdenek Sumnik (Prague, Czech Republic)
Hall 1
15:30S8.1Disentangling disease and drug signatures in the human gut microbiome
16:00S8.2The role of the gut microbiome for immunity and metabolism
16:30S8.3Gut microbiome modulates the risk for islet autoimmunity
15:30-17:00Symposium 9 - Childhood Craniopharyngioma: Recent Advances
Chair(s): Lidia Castro (Santiago de Compostela, Spain) & Helen Spoudeas (London, UK)
Hall 2
15:30S9.1Outcomes in patients with childhood craniopharyngioma
16:00S9.2Surgical approach to craniopharyngioma
16:30S9.3Potential novel therapies for craniopharyngioma: Insights from a mouse model
15:30-17:00Symposium 10 - Growth plate & nutrition
Chair(s): Faisal Ahmed (Glasgow, UK) & Agnes Linglart (Paris, France)
Hall 4
15:30S10.1Molecular mechanisms of growth plate adaptation during undernutrition
16:00S10.2Molecular response of the growth plate to inflammatory cytokines
16:30S10.3Bone health in chronic disease
15:30-16:30Meet the Expert Sessions
MTE5.2Management of the adolescent with CAH
MTE6.2Management of Prader-Willi syndrome in toddlers
MTE8.2Looking beyond nutritional rickets: From the foetus to the infant
17:00-17:30Coffee Break
17:30-17:45President Poster Award
Chair(s): Laura Audí (Barcelona, Spain)
Hall 1
17:45-18:15Plenary 6
Chair(s): Peter Clayton (Manchester, UK) & Mitch Geffner (Los Angeles, UK)
Hall 1
17:45PL6The complex relationship between the GH/IGF axis and aging and longevity – the interface with diet and mitochondrial peptides
18:15-18:30Closing Ceremony
Chair(s): Laura Audí (Barcelona, Spain), Peter Clayton (Manchester, UK) & Jean-Claude Carel (Paris, France)
Hall 1
19:00-23:59ESPE Evening